摘要
目的研究分析脂蛋白相关磷脂酶A2(lipoprotein-associated phospholipase A2,Lp-PLA2)与冠心病患者左心功能的相关性,并探讨厄贝沙坦干预对冠心病患者的作用。方法选取2016年1月~2018年3月我院收治的116例冠心病患者与我院行健康体检的50例健康志愿者,分别设为冠心病组、对照组,采集其空腹外周静脉血,检测血浆Lp-PLA2表达水平,比较冠心病组与对照组的血浆Lp-PLA2表达水平,并比较两组的左心射血分数。根据左心射血分数将冠心病组患者分为左心功能不全组、左心功能正常组,比较不同左心功能患者的血浆Lp-PLA2表达水平,并分析血浆Lp-PLA2表达水平与冠心病患者左心功能的相关性。针对冠心病患者实施厄贝沙坦药物干预,比较治疗前后患者的左心射血分数、血浆Lp-PLA2表达水平。结果冠心病组的血浆Lp-PLA2表达水平高于对照组(P<0.05);冠心病组的左心射血分数低于对照组(P<0.05);左心功能不全组的血浆Lp-PLA2表达水平高于左心功能正常组(P<0.05),血浆Lp-PLA2表达水平与左心功能呈负相关(r=-0.783,P<0.05)。经厄贝沙坦治疗后,冠心病患者的左心射血分数较治疗前增高(P<0.05),其血浆Lp-PLA2表达水平较治疗前降低(P<0.05)。结论冠心病患者的血浆Lp-PLA2表达水平普遍上调,血浆Lp-PLA2表达水平可对冠心病患者左心功能予以反映,而经厄贝沙坦干预可有效改善患者左心功能,促使其血浆Lp-PLA2表达水平下调。
Objective To study the analysis of lipoprotein associated phospholipase A2（lipoprotein-associated phospholipase A2, Lp-PLA2） and the correlation of left heart function in patients with coronary heart disease（CHD）, and explore he sand and the effect of intervention in patients with coronary heart disease（CHD）. Methods A total of 116 cases of patients with coronary heart disease（CHD） and 50 cases of healthy volunteers with physical examination in the hospital from January 2016 to March 2018 were selected and set to coronary heart disease group and the control group respectively. The level of plasma Lp-PLA2 expression was measured and the level of plasma Lp-PLA2 expression was compared between the coronary heart disease group and the control group, and the left cardiac ejection fraction of the two groups was compared. According to the left cardiac ejection fraction, the patients in the coronary heart disease group were divided into left heart dysfunction group and normal left heart function group. The plasma Lp-PLA2 expression level of patients with different left heart function was compared, and the correlation between plasma Lp-PLA2 expression level and left heart function of patients with coronary heart disease was analyzed. Irbesartan drug intervention was applied to patients with coronary heart disease. The left ventricular ejection fraction and plasma Lp-PLA2 level were compared before and after treatment. Results The expression level of plasma Lp-PLA2 in the CHD group was higher than that in the control group（P〈0.05）. The left cardiac ejection fraction in the CHD group was lower than the control group（P〈0.05）. The expression level of plasma Lp-PLA2 in the left cardiac dysfunction group was higher than that in the left cardiac function group（P〈0.05）, and the expression level of plasma Lp-PLA2 was negatively correlated with the left cardiac function（r=-0.783, P〈0.05）. After treatment with irbesartan, the left cardiac ejection fraction of the patients with coronary heart d
作者
何鼎洋
赵新生
黄创杰
HE Ding-yang;ZHAO Xin-sheng;HUANG Chuang-jie(First Department of Medicine,Nanhai Seventh People＇s Hospital in Foshan City,Guangdong Province,Foshan 528247,China)
出处
《中国当代医药》
2018年第25期72-74,共3页
China Modern Medicine
关键词
冠心病
脂蛋白相关磷脂酶A2
左心功能
相关性
厄贝沙坦
Coronary heart disease
Lipoprotein associated phospholipase A2
Left ventricular function
Correlation
Irbesartan
